S. 1280 · 118th Congress (2023–2025)
TRANQ Research Act of 2023
This bill requires the National Institute of Standards and Technology (NIST) to support research and other activities related to identifying xylazine (a compound used in veterinary medicine as a nonopioid tranquilizer), novel synthetic opioids, and other new psychoactive substances.
In particular, NIST must support
- basic measurement science and research, including graduate and postgraduate research;
- near-real time spectrometry capabilities (i.e., a technique for rapidly identifying the chemical composition of a substance);
- strategies and voluntary best practices for handling, transporting, and analyzing such substances; and
- collaboration with other government agencies, institutions of higher education, and the private sector to enhance relevant narcotic and opioid detection and analysis capabilities.
The Government Accountability Office must evaluate the capability of the federal government to respond to the threats posed by new psychoactive substances like xylazine, including with respect to available technology and laboratories.
Show official title
A bill to require coordinated National Institute of Standards and Technology science and research activities regarding illicit drugs containing xylazine, novel synthetic opioids, and other substances of concern, and for other purposes.
Expired in Senate committee
Derived from the legislative history, not an official disposition.
Latest actionReported by committee
This bill’s path
This is S. 1280’s recorded path, not a universal congressional workflow.
How bills become lawAll actionsIntroduced
Passed Senate
Passed House
Sent to President
Signed into law
Expired
- Sponsor
- Sen. Ted Cruz (R-TX)
- Cosponsors
5 cosponsors
1 original · 4 later
- Sen. Peter Welch (D-VT)· Original · Apr 25, 2023
- Sen. Shelley Moore Capito (R-WV)· Later · May 31, 2023
- Sen. Raphael G. Warnock (D-GA)· Later · May 31, 2023
- Sen. Marsha Blackburn (R-TN)· Later · Jun 13, 2023
- Sen. Maria Cantwell (D-WA)· Later · Jun 13, 2023
- Policy area
- Science, Technology, Communications
- Subjects
- Advanced technology and technological innovations
- Chemistry
- Congressional oversight
- Drug trafficking and controlled substances
- Higher education
- Research administration and funding
- Science and engineering education
On this page
Timeline
i
In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.
Introduced in Senate
Document: Introduced in Senate
Sources
- Congress.gov action
- Library of Congress
- Latest
▸ 3 committee actions · Apr 25, 2023 – Dec 13, 2023
Referred to committee
Read twice and referred to the Committee on Commerce, Science, and Transportation.
Sources
- Congress.gov action
- Senate
Ordered reported
Committee on Commerce, Science, and Transportation. Ordered to be reported with an amendment in the nature of a substitute favorably.
Sources
- Congress.gov action
- Senate
Reported by committee
Committee on Commerce, Science, and Transportation. Reported by Senator Cantwell with an amendment in the nature of a substitute. Without written report.
Sources
- Congress.gov action
- Senate
Expired
Introduced → Reported by committee → No further action before the 118th Congress ended.
Committees
- SenateCommerce, Science, and TransportationReferred Apr 25, 2023 · Markup May 10, 2023 · Reported Dec 13, 2023
May 10, 2023 · Meeting
Text & titles
i
Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.
Titles (3)
TRANQ Research Act of 2023
Display title, Short title · Introduced in Senate, Reported to Senate
Testing, Rapid Analysis, and Narcotic Quality Research Act of 2023
Short title · Introduced in Senate, Reported to Senate
A bill to require coordinated National Institute of Standards and Technology science and research activities regarding illicit drugs containing xylazine, novel synthetic opioids, and other substances of concern, and for other purposes.
Official title · Introduced in Senate